Volume 12, number 3
 PDF Downloads: 516

Analysis of PDLIM4 Expression in Different Subtypes of Breast Cancer  

Kravchenko Dmitry Sergeevich1,2, Yuriy Nikolaevich Lezhnin1,2, Elena Ivanovna Frolova1*  

1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences 117997, Russian Federation, Moscow, GSP-7, Ulitsa Miklukho-Maklaya, 16/10 2Engelhardt Institute of Molecular Biology, Russian Academy of Sciences 119991 Moscow, Russia  

DOI : http://dx.doi.org/10.13005/bbra/1866

ABSTRACT: PDLIM4 is an adapter protein which is frequently silenced in different types of cancer, and is eventually induced in the event of  phenotypic reversion of cancer cells. Little is known about specific mechanisms that underly involvement of PDLIM4 in the processes of malignant transformation and reversion; several data suggest that PDLIM4 could function as a regulator of c-Src tyrosine kinase activity, other observations indicate that its participation is not mandatory for c-Src regulation. In this study we explored PDLIM4 role as a possible indicator of molecular subtype of breast cancer. We performed RNA sequencing on the panel of breast cancer cell lines grouped by PDLIM4 status and compared their expression profiles with those of different breat cancer subtypes, and observed a correlation between PDLIM4 status and claudin-low phenotype, which may indicate involvement of PDLIM4 in distinct pathologic pathways that lead to malignant transformation of breast epithelium.

KEYWORDS: PDLIM4; RIL; Breast cancer; Claudin-low; Subtypes

Download this article as: 
Copy the following to cite this article:

Sergeevich K. D, Lezhnin Y. N, Frolova E. I. Analysis of PDLIM4 Expression in Different Subtypes of Breast Cancer. Biosci Biotech Res Asia 2015;12(3)

Copy the following to cite this URL:

Sergeevich K. D, Lezhnin Y. N, Frolova E. I. Analysis of PDLIM4 Expression in Different Subtypes of Breast Cancer. Biosci Biotech Res Asia 2015;12(3). Available from: http://www.biotech-asia.org/?p=3710>

[ HTML Full Text]

Back to TOC